Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.63 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 10/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribose (Furanose) SCHEMBL2728051 | 0.84 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Uridine SCHEMBL28023784 | 0.82 | SLC28A1 (0.92) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL8923978 | 0.80 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL8925514 | 0.80 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL13868072 | 0.80 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Cytarabine SCHEMBL1829999 | 0.79 | LMNA (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL14853938 | 0.77 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Uridine SCHEMBL9060684 | 0.77 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Arauridine SCHEMBL359587 | 0.77 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Uridine SCHEMBL20987631 | 0.77 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209695-A1 | Pharmaceutical Compositions for High-Capacity Targeted Delivery | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2019-07-11 | — | — | US | disclosed |
| US-10105446-B2 | Pharmaceutical compositions for high-capacity targeted delivery | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180016601-A1 | Methods for Modulating Genome Editing | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2018-01-18 | — | — | US | disclosed |
| US-20170014521-A1 | PHARMACEUTICAL COMPOSITIONS FOR HIGH-CAPACITY TARGETED DELIVERY | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2017-01-19 | — | — | US | disclosed |
| US-9486533-B2 | Pharmaceutical compositions for high-capacity targeted delivery | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2016-11-08 | — | — | US | disclosed |
| WO-2016115326-A1 | METHODS FOR MODULATING GENOME EDITING | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-07-21 | — | — | WO | disclosed |
| US-20160145619-A1 | MULTIVALENT APTAMER COMPLEXES | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2016-05-26 | — | — | US | disclosed |
| US-9284559-B2 | Multivalent aptamer complexes | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150094359-A1 | PHARMACEUTICAL COMPOSITIONS FOR HIGH-CAPACITY TARGETED DELIVERY | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2015-04-02 | — | — | US | disclosed |
| US-8940885-B2 | Cytotoxic nucleotides for targeted therapeutics | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2015-01-27 | — | — | US | disclosed |
| US-20110213135-A1 | Cytotoxic Nucleotides for Targeted Therapeutics | GMEINER WILLIAM H | 2011-09-01 | — | — | US | disclosed |
| US-20100261781-A1 | MULTIVALENT APTAMER COMPLEXES | GMEINER WILLIAM H | 2010-10-14 | — | — | US | disclosed |
| US-20080026947-A1 | Cytotoxic nucleotides for targeted therapeutics | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2008-01-31 | — | — | US | disclosed |
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | WELLSTAT BIOCATALYSIS, LLC | 2005-06-09 | — | — | US | disclosed |
| US-6702705-B1 | Prodrugs activated by targeted catalytic proteins | IGEN INTERNATIONAL, INC. | 2004-03-09 | — | — | US | disclosed |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | IGEN, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6258360-B1 | BENZOATE CONJUGATES; ANTITUMOR AGENTS | IGEN INTERNATIONAL, INC. | 2001-07-10 | — | — | US | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209695-A1 | Pharmaceutical Compositions for High-Capacity Targeted Delivery | EPHA2, CD2BP2, ADGRE5 | SLC28A1 449/4885SLC28A2 482/4885SLC29A1 67/4885 |
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | SLC28A1 2502/4885SLC28A2 2810/4885SLC29A1 823/4885 |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | SLC28A1 2502/4885SLC28A2 2810/4885SLC29A1 823/4885 |
| US-10105446-B2 | Pharmaceutical compositions for high-capacity targeted delivery | EPHA2, CD2BP2, ADGRE5 | SLC28A1 449/4885SLC28A2 482/4885SLC29A1 67/4885 |
| US-20150094359-A1 | PHARMACEUTICAL COMPOSITIONS FOR HIGH-CAPACITY TARGETED DELIVERY | EPHA2, CD2BP2, ADGRE5 | SLC28A1 449/4885SLC28A2 482/4885SLC29A1 67/4885 |
| US-20170014521-A1 | PHARMACEUTICAL COMPOSITIONS FOR HIGH-CAPACITY TARGETED DELIVERY | EPHA2, CD2BP2, ADGRE5 | SLC28A1 449/4885SLC28A2 482/4885SLC29A1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.